First AD

Second AD

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Strategies for Managing Treatment-Naïve CLL with High-Risk Features

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia

Peer Exchange

UCI Health Chao Family Comprehensive Cancer Center

Cancer Centers

Partner

Cleveland Clinic

Atrium Health Levine Cancer

Moffitt Cancer Center

Rutgers Cancer Institute

Current Front-Line Treatment Options for CLL in 2023

Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

Expert Insights into Investigation Therapies for CLL

Future Perspectives on the Treatment Landscape for CLL